

Alzheimer's Disease (AD)

## Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

**Trial Status**  
Recruiting

**Trial Runs In**  
8 Countries

**Trial Identifier**  
NCT07177352 WP45722

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

### Official Title:

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

### Trial Summary:

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

**NCT07177352 WP45722**  
Trial Identifiers

### Eligibility Criteria:

**Gender**  
All

**Age**  
#50 Years & # 90 Years

**Healthy Volunteers**  
No

### Inclusion Criteria:

- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

### Exclusion Criteria:

- Dependency in basic activities of daily living (bADLs) due to cognitive impairment
- Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)

# ForPatients

*by Roche*

- Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
- History of severe, clinically significant central nervous system trauma
- Any serious medical condition that precludes a participant's safe participation and completion of a clinical study